Double Blind Comparative Study of TAK-875

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-05-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and safety of treatment with TAK-875 in diabetic patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Double-blind Comparative Study of TAK-875

NCT01433393

Diabetes Mellitus

COMPLETED PHASE3

TAK-875 Glimepiride Drug-Interaction Study

NCT01496443

Pharmacokinetics

COMPLETED PHASE1

Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus

NCT01007097

Diabetes Mellitus, Type 2

COMPLETED PHASE2

Long-term Study of TAK-875

NCT01433406

Diabetes Mellitus

COMPLETED PHASE3

Open-label Study of TAK-875

NCT01433419

Diabetes Mellitus

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Patients

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAK-875 25 mg

Group Type EXPERIMENTAL

TAK-875

Intervention Type DRUG

TAK-875 50 mg

Group Type EXPERIMENTAL

TAK-875

Intervention Type DRUG

Glimepiride

Group Type ACTIVE_COMPARATOR

Glimepiride

Intervention Type DRUG

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAK-875

Intervention Type DRUG

TAK-875

Intervention Type DRUG

Glimepiride

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant is an outpatient.
* The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria

* The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
* The participant is considered ineligible for the study for any other reason by the investigator or subinvestigator.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No